Introduction
Spontaneous clearance of hepatitis C virus (HCV) occurs in the nontransplant population at a rate of approximately 15%. However, in immunocompromised renal transplant patients, this is an extremely rare occurrence. 1 It has occasionally been reported after reduction or withdrawal of immunosuppressive agents. 2 We describe a case of a renal transplant recipient who acquired post-transplant HCV with progressive liver disease but subsequently experienced spontaneous viral clearance after reduction of immunosuppression. This case underscores the importance of restoration of the immune system in the control of hepatitis C virus viremia and disease progression and the need to minimize or obviate immunosuppression in such patients.
Case summary
A 36-year-old woman presented to us in February 2007 for management of chronic renal disease (stage 5) of obscure etiology. She was started on thrice a week maintenance hemodialysis from left forearm AV fistula. She underwent living donor (Brother) renal transplant in August 2007 and was in good health with stable graft function till December 2011, i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 1 1 3 -1 1 5 a r t i c l e i n f o when she presented with jaundice (Total bilirubin -4.8 mg/dL) and transaminitis (AST -194 IU/L and peak ALT of 1444 IU/L). All antecedent liver tests were normal. There was no history of blood transfusion or high-risk behavior. Serological tests for hepatitis B virus, CMV, EBV and HIV were negative. She tested positive for anti-HCV antibody with 0.78 million IU/mL HCV RNA copies (Genotype 1a). Her ultrasound abdomen and hepatic elastography by ARFI scan did not show evidence of liver cirrhosis. She was managed conservatively during that episode. She continued to have intermittent hyperbilirubinemia and transaminitis on follow-up. Hepatic decompensation in the form of hypoalbuminemia and coagulopathy were evident over the next 3 months. HCV RNA copies were persistently high on two occasions ( Fig. 1) . In October 2012, she was admitted for hepatic decompensation in the form of ascites, upper gastrointestinal bleed, and hepatic encephalopathy. She had hyperbilirubinemia and transaminitis. Spontaneous bacterial peritonitis was ruled out on diagnostic paracentesis and OGD scopy showed erosive gastritis. She was offered therapy for HCV (pegylated interferon + ribavirin), which she declined due to the imminent risk of renal allograft loss. She improved with supportive treatment and her immunosuppression was gradually reduced to tacrolimus -0.5 mg/day, mycophenolate mofetil -180 mg/day, and prednisolone -5 mg/day. The trough tacrolimus levels were maintained in the range of 2-3 ng/mL. Her signs of liver cell failure persisted with stable renal allograft function.
In September 2013, she was admitted with grade II hepatic encephalopathy, deep icterus (Total bilirubin -9 mg/dL, Direct bilirubin -7.2 mg/dL), transaminitis (AST -198 IU/L, ALT -1124 IU/L), and upper gastrointestinal bleed. She had coagulopathy (INR -2.6, PTT -54) and hypoalbuminemia (1.8 mg/dL). Ultrasound abdomen showed coarse echotexture of liver and erosive gastritis on OGD scopy. There was evidence of acute renal injury (creatinine of 1.8 mg/dL) with clinical impression of hepatorenal syndrome. She was categorized Child Turcotte Pugh-B, MELD score of 18, and so living donor liver transplant was offered. The patient and her sister, as donor, were evaluated by the liver transplant team. Till the financial matters were arranged, she gradually recovered from the acute hepatic and renal injury with supportive management after hospital stay of one month and was discharged after enlisting on the cadaver liver recipient list. On follow-up over the next 4 months, she improved significantly with normalizing of liver function test and decreasing ascites. In February 2014, her HCV RNA by RT PCR fell down to less than 0.5 IU/mL for the first time, which was confirmed on two occasions, two months apart. Liver transplantation was hence deferred and patient was followed up (Fig. 2) . She is currently on tacrolimus -0.5 mg/day, MMF -180 mg/day, and prednisolone 5 mg/day and has a stable graft function with a creatinine of 1.1 mg%. Her liver function tests are stable (AST -32 IU/L, ALT -43 IU/L, Albumin -3.7 mg/dL, INR -1.2) with normal ultrasound liver and ARFI scan and continue to be negative for anti-HCV on follow-up. Liver biopsy confirmation of complete clearance of viremia was advised but was declined by the relatives.
Discussion
After acute infection, HCV has a remarkable predilection for chronicity. As few as 15% of patients successfully clear acute infection, and this seems related to the initial vigor of the cellular immune response. Determinants of the rate of chronic HCV disease progression include infants, male sex, alcohol use, viral co-infection (HBV, HIV), and immunosuppression. The immune response is critical to the containment and clearance of viral infection. Patients who have cleared acute hepatitis C show a brisk CD4 T-cell response. 3 HCV-infected solid organ transplant recipients immunosuppressed with medications have impaired virus-specific T-cell responses and higher viral RNA levels and experience accelerated disease progression related to the intensity of immunosuppression. 4 Under immunosuppression, the patient is unable to mount an effective HCV-specific immune response and eradicate initial viremia. Treatment with interferon is not often an option for renal allograft recipients with concurrent HCV, due to high rates of graft rejection and secondary loss due to its immunomodulatory effects. Outcome in such patients is poor with 85% i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 1 1 3 -1 1 5 chronicity and hepatic decompensation and liver fibrosis. Spontaneous clearance in HCV-infected renal transplant patients is extremely rare with only few cases reported in literature. 2, 5, 6 Plausible mechanism in all the cases was immune reconstitution following reduction of immunosuppression. As in our case, while the patient was on minimal immunosuppressive agents, her native immune system successfully and spontaneously cleared the HCV. This clearance was preceded by the probable intense immune response mounted by the native immunity manifesting as brisk transaminitis and hepatic decompensation, as seen during her last admission. This represents a 'clearance phase hepatitis', perhaps caused by a host immune response or reconstitution, or as an yet undefined immunological phenomenon. Additionally, in our case, the young age, the absence of alcohol consumption, and female sex were contributory in clearing of the HCV. Though the cases mentioned of spontaneous clearance have received interferon prior to transplant, our patient was interferon naïve, which is an extremely rare case.
The finding of spontaneous clearance of HCV on minimization of immunosuppression in a renal transplant recipient underscores the importance of the immune system in the control of disease. Efforts to minimize or obviate immunosuppression in transplant recipients may have a profound effect on the natural history of HCV in these hosts. To the best of our knowledge, this is the first such reported case in Indian literature.
